Down 30% In A Month, Is There More Pain For ChemoCentryx Stock?
- Tuesday, February 1, 2022, 6:15
- Market
- Add a comment
The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has seen a fall of 30% over the last month. The broader S&P 500 Health Care index is down close to 10% over the last month due to…
About the Author
admin123 has written 23410 stories on this site.
